Applied Therapeutics (APLT)
(Real Time Quote from BATS)
$4.26 USD
-0.05 (-1.16%)
Updated Apr 25, 2024 01:06 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Applied Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 50 | 31 | 81 | 97 | 39 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 7 | 8 | 6 | 7 |
Total Current Assets | 54 | 37 | 88 | 103 | 46 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 55 | 38 | 90 | 105 | 48 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 5 | 9 | 1 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 15 | 17 | 20 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 54 | 14 | 0 | 0 | 0 |
Total Current Liabilities | 71 | 33 | 26 | 21 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 72 | 34 | 27 | 23 | 16 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 451 | 353 | 329 | 243 | 99 |
Retained Earnings | -469 | -349 | -266 | -161 | -67 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -17 | 4 | 63 | 82 | 33 |
Total Liabilities & Shareholder's Equity | 55 | 38 | 90 | 105 | 48 |
Total Common Equity | -17 | 4 | 63 | 82 | 33 |
Shares Outstanding | 84.80 | 48.00 | 26.20 | 22.40 | 21.60 |
Book Value Per Share | -0.20 | 0.08 | 2.39 | 3.66 | 1.51 |
Fiscal Year End for Applied Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 50 | 37 | 36 | 23 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 4 | 7 | 7 | 6 |
Total Current Assets | NA | 54 | 44 | 43 | 29 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 55 | 45 | 44 | 30 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 6 | 5 | 6 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 15 | 12 | 16 | 14 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 54 | 37 | 26 | 13 |
Total Current Liabilities | NA | 71 | 56 | 47 | 33 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 1 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 72 | 56 | 48 | 34 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 451 | 420 | 384 | 355 |
Retained Earnings | NA | -469 | -431 | -389 | -359 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -17 | -11 | -4 | -4 |
Total Liabilities & Shareholder's Equity | NA | 55 | 45 | 44 | 30 |
Total Common Equity | 0 | -17 | -11 | -4 | -4 |
Shares Outstanding | 105.80 | 84.80 | 63.10 | 57.80 | 48.10 |
Book Value Per Share | 0.00 | -0.20 | -0.17 | -0.07 | -0.08 |